Literature DB >> 30455380

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.

Anton W Langerak1, Matthias Ritgen2, Valentin Goede3,4, Sandra Robrecht4, Jasmin Bahlo4, Kirsten Fischer4, Michael Steurer5, Marek Trněný6, Stephen P Mulligan7, Ulrich J M Mey8, Kerstin Trunzer9, Günter Fingerle-Rowson9, Kathryn Humphrey10, Stephan Stilgenbauer11, Sebastian Böttcher2,12, Monika Brüggemann2, Michael Hallek4,13, Michael Kneba2, Jacques J M van Dongen1,14.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30455380      PMCID： PMC6356981          DOI： 10.1182/blood-2018-03-839688

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  22 in total

Review 1.  Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.

Authors:  Philip A Thompson; William G Wierda
Journal:  Blood       Date:  2015-11-17       Impact factor: 22.113

2.  Minimal residual disease is an independent predictor for 10-year survival in CLL.

Authors:  Marwan Kwok; Andy C Rawstron; Abraham Varghese; Paul A S Evans; Sheila J M O'Connor; Chi Doughty; Darren J Newton; Paul Moreton; Peter Hillmen
Journal:  Blood       Date:  2016-10-03       Impact factor: 22.113

Review 3.  Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia.

Authors:  Carolyn Owen; Anna Christofides; Nathalie Johnson; Tatiana Lawrence; David MacDonald; Carol Ward
Journal:  Leuk Lymphoma       Date:  2017-05-16

4.  NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.

Authors:  William G Wierda; Andrew D Zelenetz; Leo I Gordon; Jeremy S Abramson; Ranjana H Advani; C Babis Andreadis; Nancy Bartlett; John C Byrd; Paolo Caimi; Luis E Fayad; Richard I Fisher; Martha J Glenn; Thomas M Habermann; Nancy Lee Harris; Francisco Hernandez-Ilizaliturri; Richard T Hoppe; Steven M Horwitz; Mark S Kaminski; Christopher R Kelsey; Youn H Kim; Susan Krivacic; Ann S LaCasce; Michael G Martin; Auayporn Nademanee; Pierluigi Porcu; Oliver Press; Rachel Rabinovitch; Nishitha Reddy; Erin Reid; Kenneth Roberts; Ayman A Saad; Erin D Snyder; Lubomir Sokol; Lode J Swinnen; Julie M Vose; Joachim Yahalom; Mary A Dwyer; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2017-03       Impact factor: 11.908

5.  A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL.

Authors:  Natalie Dimier; Paul Delmar; Carol Ward; Rodica Morariu-Zamfir; Günter Fingerle-Rowson; Jasmin Bahlo; Kirsten Fischer; Barbara Eichhorst; Valentin Goede; Jacques J M van Dongen; Matthias Ritgen; Sebastian Böttcher; Anton W Langerak; Michael Kneba; Michael Hallek
Journal:  Blood       Date:  2017-12-18       Impact factor: 22.113

6.  Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.

Authors:  Sebastian Böttcher; Matthias Ritgen; Kirsten Fischer; Stephan Stilgenbauer; Raymonde M Busch; Günter Fingerle-Rowson; Anna Maria Fink; Andreas Bühler; Thorsten Zenz; Michael Karl Wenger; Myriam Mendila; Clemens-Martin Wendtner; Barbara F Eichhorst; Hartmut Döhner; Michael J Hallek; Michael Kneba
Journal:  J Clin Oncol       Date:  2012-02-13       Impact factor: 44.544

7.  Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.

Authors:  Gabor Kovacs; Sandra Robrecht; Anna Maria Fink; Jasmin Bahlo; Paula Cramer; Julia von Tresckow; Christian Maurer; Petra Langerbeins; Günter Fingerle-Rowson; Matthias Ritgen; Michael Kneba; Hartmut Döhner; Stephan Stilgenbauer; Wolfram Klapper; Clemens-Martin Wendtner; Kirsten Fischer; Michael Hallek; Barbara Eichhorst; Sebastian Böttcher
Journal:  J Clin Oncol       Date:  2016-11-01       Impact factor: 44.544

Review 8.  Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective.

Authors:  Carolyn J Owen; Douglas A Stewart
Journal:  Ther Adv Hematol       Date:  2015-08

Review 9.  Management of Chronic Lymphocytic Leukemia in the Elderly.

Authors:  Jacqueline C Barrientos
Journal:  Cancer Control       Date:  2015-10       Impact factor: 3.302

Review 10.  Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic Leukemia.

Authors:  Sarah S Evans; Amber B Clemmons
Journal:  J Adv Pract Oncol       Date:  2015-07-01
View more
  6 in total

Review 1.  Stance of MRD in Non-Hodgkin's Lymphoma and its upsurge in the novel era of cell-free DNA.

Authors:  S Garg; A Kumar; R Gupta
Journal:  Clin Transl Oncol       Date:  2021-05-15       Impact factor: 3.405

2.  Measurable residual disease testing in chronic lymphocytic leukaemia: hype, hope neither or both?

Authors:  Shenmiao Yang; Neil E Kay; Min Shi; Gert Ossenkoppele; Roland B Walter; Robert Peter Gale
Journal:  Leukemia       Date:  2021-09-27       Impact factor: 11.528

Review 3.  Frontline therapies for untreated chronic lymphoid leukemia.

Authors:  Delong Liu; Juanjuan Zhao
Journal:  Exp Hematol Oncol       Date:  2019-08-17

4.  Battle of Thermopylae: 300 Spartans (natural killer cells plus obinutuzumab) versus the immortal warriors (chronic lymphocytic leukemia cells) of Xerxes' army.

Authors:  Ricardo García-Muñoz; María-Josefa Nájera; Jesús Feliu; Judith Antón-Remírez; Enrique Ramalle-Gómara; Raquel Marín-Gorricho; Raisa Peralta; Elena Gutiérrez-Gamarra; Jessica Nuñez-Rodriguez; Ricardo Zafra-Morales; Lorea Aguinaga; María-Jose Nebot-Villacampa; Prisma-Monserrat Hernandez-Pérez; Giovanna Farfán-Quiroga; Carlos Panizo; Elena Domínguez-Garrido
Journal:  Future Sci OA       Date:  2019-11-26

Review 5.  Sequential and combination treatments with novel agents in chronic lymphocytic leukemia.

Authors:  Moritz Fürstenau; Michael Hallek; Barbara Eichhorst
Journal:  Haematologica       Date:  2019-10-04       Impact factor: 9.941

Review 6.  Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?

Authors:  Moritz Fürstenau; Nisha De Silva; Barbara Eichhorst; Michael Hallek
Journal:  Hemasphere       Date:  2019-08-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.